IP Library Granted Patent US 11,103,459
Granted Patent B2
US 11,103,459 · App. 16/151,736 · Granted Aug 31, 2021

Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

Inventors: Mark Hokenson (Camarillo, CA); Keith A. Oberg (Valencia, CA)
Assignee: MannKind Corporation
A61K9/1676A61K9/0073A61K9/167A61K9/1611A61K9/1617A61K9/1623A61K9/5052A61K9/5089A61K38/13A61K38/22A61K38/25A61K38/26A61K38/27A61K38/28A61K38/29
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,103,459
App. No.
16/151,736
Granted
Aug 31, 2021
Kind
B2
Abstract

Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Claims (21)

1. A method for making a microparticle coated with an active agent that is of pharmaceutical use, the method comprising:

(i) obtaining a crystalline fumaryl diketopiperazine microparticle wherein the crystalline diketopiperazine microparticle does not comprise an active agent;

(ii) forming a suspension comprising said crystalline diketopiperazine microparticle and a solvent;

(iii) dissolving said active agent in the fluid phase of said suspension;

(iv) increasing the pH of the fluid phase to about 4 to 5;

(v) adsorbing of said active agent onto a surface of said crystalline fumaryl diketopiperazine microparticle to provide a coating of said active agent on said crystalline fumaryl diketopiperazine microparticle; and

(vi) removing or exchanging said solvent after step (v).

2. The method of claim 1 , wherein the active agent is a protein, peptide, or polypeptide.

3. The method of claim 1 , wherein the active agent is glucagon-like peptide 1 (GLP-1).

4. The method of claim 1 , wherein the active agent is vasoactive.

5. The method of claim 1 , wherein the active agent is a neuroactive agent.

6. The method of claim 1 , wherein the active agent is a hormone.

7. The method of claim 1 , wherein the active agent is an anticoagulant.

8. The method of claim 1 , wherein the active agent is an immunomodulating agent.

9. The method of claim 1 , wherein the active agent is a cytotoxic agent.

10. The method of claim 1 , wherein the active agent is an antibiotic agent.

11. The method of claim 1 , wherein the active agent is an antiviral agent.

12. The method of claim 1 , wherein the active agent is an antigenic agent.

13. The method of claim 1 , wherein the active agent is an antibody.

14. The method of claim 1 , wherein the active agent is a small molecule.

15. The method of claim 1 , wherein the active agent is a nucleic acid molecule.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded Aug 12, 2025
From: MANNKIND CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072444/0525 →
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2018
From: HOKENSON, MARK; OBERG, KEITH A.
To: MANNKIND CORPORATION
Reel/Frame 047070/0887 →
Continuity (7)
Division 15233794 · Aug 10, 2016
Continuation 14746656 · Jun 22, 2015
Division 12883369 · Sep 16, 2010
Continuation 11532065 · Sep 14, 2006
Provisional Application 60717524 · Sep 14, 2005
Provisional Application 60744882 · Apr 14, 2006
Related Publication 20190029961A1 · Jan 31, 2019